Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

K. Burnett, Alan; K. Hills, Robert; Milligan, Donald; Kjeldsen, Lars; Kell, Jonathan; H. Russell, Nigel; A. Liu Yin, John; Hunter, Ann; H. Goldstone, Anthony; Wheatley, Keith

doi:10.1200/jco.2010.31.4310

Public

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

Published in Journal of Clinical Oncology • Dec 21, 2010

Authors:

Alan K. Burnett

Robert K. Hills

Donald Milligan

Abstract

PURPOSE: Antibody-directed chemotherapy for acute myeloid leukemia (AML) may permit more treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin (GO) is an immunoconjugate between CD33 and calicheamicin that is internalized when binding to the epitope. We previously establish...

Subject

Gemtuzumab ozogamicin

Medicine

Acute myeloblastic leukemia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!